Compare ESS & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESS | WST |
|---|---|---|
| Founded | 1971 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 20.1B |
| IPO Year | 1994 | N/A |
| Metric | ESS | WST |
|---|---|---|
| Price | $256.53 | $280.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 10 |
| Target Price | $292.97 | ★ $346.78 |
| AVG Volume (30 Days) | 415.9K | ★ 661.6K |
| Earning Date | 10-29-2025 | 10-23-2025 |
| Dividend Yield | ★ 4.03% | 0.31% |
| EPS Growth | ★ 53.64 | 0.17 |
| EPS | ★ 13.15 | 6.75 |
| Revenue | $1,916,711,000.00 | ★ $3,017,900,000.00 |
| Revenue This Year | $3.80 | $7.01 |
| Revenue Next Year | $3.59 | $6.20 |
| P/E Ratio | ★ $19.42 | $41.51 |
| Revenue Growth | ★ 9.37 | 4.92 |
| 52 Week Low | $243.25 | $187.43 |
| 52 Week High | $316.29 | $348.90 |
| Indicator | ESS | WST |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 55.28 |
| Support Level | $258.24 | $269.08 |
| Resistance Level | $262.87 | $285.54 |
| Average True Range (ATR) | 4.01 | 7.15 |
| MACD | -0.01 | 1.29 |
| Stochastic Oscillator | 30.46 | 82.62 |
Essex Property Trust owns a portfolio of 258 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.